Use: As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus Usual Adult Dose for Weight Loss ORAL: Wegovy Tablets: Initial dose (days 1 through 30): 1.5 mg orally once a day Dose escalation: Days 31 through 60: 4 mg orally once a day Days 61 through 90: 9 mg orally once a day SUBCUTANEOUS: Wegovy Injection: Initial dose (weeks 1 through 4): 0.25 mg subcutaneously once a week Dose escalation: Weeks 5 through 8: 0.5 mg subcutaneously once a week Weeks 9 through 12: 1 mg subcutaneously once a week Weeks 13 through 16: 1.7 mg subcutaneously once a week If the 2.4 mg dosage is tolerated for at least 4 weeks and additional weight reduction is clinically indicated: Increase to 7.2 mg subcutaneously once a week
CWMP providers qualify for up to 6 AMA PRA Category 1 CME credits per year upon completing their annual recertification requirements
In diabetes studies, about 4 to 7 out of 10 people experience some stomach problems, but most are mild
No lifelong dependency required
Validated analytical methodologies are essential for accurately monitoring and quantifying these degradation processes
Aging, chronic stress, poor diet, alcohol, and illness all deplete NAD level The Process: Some slight discomfort may be experienced after the shot, but this goes away quickly
